en · de · es
aod-9604-notes.peptides4962.com › Info › Identity And Research Origin — Field Notes

Identity And Research Origin — Field Notes

By Editorial Desk · published 2025-09-04 · last reviewed 2025-10-19 · Info

A practical reference on peptide hormone: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.

This page was last updated on 2025-10-19 and is reviewed periodically as new material appears.

Identity and Research Origin

Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.

AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.

Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.

Research and Regulatory Status

Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.

AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.

Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.

Aod-9604 at a glance

PropertyValueNotes
Molecular classPeptide fragmentCorresponds to hGH residues 176-191
Common synonymsAOD9604, hGH 176-191Also written as AOD-9604
Typical formLyophilized powderOften supplied in sealed vials
SolubilityWater-solubleDissolves in aqueous buffers
Regulatory statusNot approved as drugBanned in sport; varies by country

Identity and Research Context

Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.

AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.

Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.

Related pages on this site

Measurement and Storage Practices

Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.

Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.

Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.

Background And Research Context

AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.

The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.

Mechanism and Regulatory Status

Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.

Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.

Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.

Reference notes

=== United Kingdom === In the U.K., as with all other vertebrates and some invertebrates, any scientific procedure which is likely to cause "pain, suffering, distress or lasting harm" is regulated by the Home Office under the Animals (Scientific Procedures) Act 1986. U.K. regulations are considered amongst the most comprehensive and rigorous in the world. Detailed data on the use of laboratory mice (and other species) in research in the U.K. are published each year. In the U.K. in 2013, there were a total of 3,077,115 regulated procedures undertaken on mice in scientific procedure establishments, licensed under the Act.

Lingual antimicrobial peptide (LAP) is a beta-defensin found in bovine internal epithelial tissue, in particular, that of the digestive tract. It has antimicrobial activity against many different pathogens. It was first isolated from an inflamed cattle tongue, hence its designation as lingual. Since then it has been found more extensively throughout the body; its presence has even been detected in bovine milk. Its expression is selective and increases in inflamed areas. LAP may have a closer relationship with immune response than simple antimicrobial activity, such as an association with growth factor activity.

Lymph contains cellular debris, bacteria, proteins, and lymphocytes, the latter of which are generated largely in the bone marrow and matured or activated in the lymph nodes, spleen, thymus, and tonsils. Lymph also transports antigen-presenting cells, such as dendritic cells, to the lymph nodes where an immune response is stimulated. B cells and T cells are the major types of lymphocytes and are derived from hematopoietic stem cells in the bone marrow. From the bone marrow, B cells immediately join the circulatory system and travel to secondary lymphoid organs in search of pathogens. T cells, on the other hand, travel from the bone marrow to the thymus, where they develop further, mature, and become immunocompetent. In the thymus, T cells are exposed to a wide variety of self-antigens; T cells can only recognize a "non-self" target only after antigens have been processed and presented in combination with the major histocompatibility complex (MHC) self-receptor. In contrast, the B cell antigen-specific receptor is an antibody molecule on the B cell surface, recognising unprocessed antigens (e.g. large molecules found on the surfaces of pathogens; small haptens, such as penicillin, attached to carrier molecules) without any need for antigen processing. Each lineage of B cell expresses a different antibody, so the complete set of B cell antigen receptors represents all the antibodies that the human body can manufacture. The secondary (or peripheral) lymphoid organs (e.g.

==== Other ==== Work is underway to develop a sCO2 closed-cycle gas turbine to operate at temperatures near 550 °C. This would have implications for bulk thermal and nuclear generation of electricity, because the supercritical properties of carbon dioxide at above 500 °C and 20 MPa enable thermal efficiencies approaching 45 percent. This could increase the electrical power produced per unit of fuel required by 40 percent or more. Given the volume of carbon fuels used in producing electricity, the environmental impact of cycle efficiency increases would be significant. Supercritical CO2 is an emerging natural refrigerant, used in new, low carbon solutions for domestic heat pumps. Supercritical CO2 heat pumps are commercially marketed in Asia. EcoCute systems from Japan, developed by Mayekawa, develop high temperature domestic water with small inputs of electric power by moving heat into the system from the surroundings. Supercritical CO2 has been used since the 1980s to enhance recovery in mature oil fields. "Clean coal" technologies are emerging that could combine such enhanced recovery methods with carbon sequestration. Using gasifiers instead of conventional furnaces, coal and water is reduced to hydrogen gas, carbon dioxide and ash. This hydrogen gas can be used to produce electrical power In combined cycle gas turbines, CO2 is captured, compressed to the supercritical state and injected into geological storage, possibly into existing oil fields to improve yields.

Wagner described the necessity of adaptation from the source material and said that the 1995 film's attempt to directly replicate the comic's motorcycle was unable to steer because the tyres were too large. Garland and VFX supervisor Jon Thum began developing the Slo-Mo concept sequences in 2009 during filming for Never Let Me Go. They experimented with an effect to replicate the visual effects of hallucinogenic drugs to see how long it could be used before it distracted the viewer from the story or action sequence. They continued to develop and modify the effect until the end of post-production, tweaking colours, colour saturation, image framing and camera motion. Slo-Mo scenes also feature a rainbow colour scheme and sparkle highlights to create an unreal and otherworldly effect. The filmmakers experimented with blood bags, prosthetics, shooting real bullets, and compressed air to see the effect of direct body hits in slow motion. In the finished film, compressed air was used to create impact ripples on flesh. Garland said the concept was inspired by nature documentaries that used high-speed photography to capture animals in slow motion. He said, "You see a whale or a shark breach the water ... then you'd stop thinking about the animal and you get transfixed by ... how water droplets connect and touch against each other. Somehow like a real [drug] trip, sort of stepping outside it but staying attached at the same time." He questioned whether the technique could be used with violence to make it purely aesthetic.

Sources: en.wikipedia.org

Notes from published material

== History == Resonance ionization was first used in a spectroscopy experiment in 1971 at the Institute for Spectroscopy Russian Academy of Sciences; in that experiment, ground state rubidium atoms were ionized using ruby lasers. In 1974, a group of photophysical researchers at the Oak Ridge National Laboratory led by George Samuel Hurst developed, for the first time, the resonance ionization process on helium atoms. They wanted to use laser light to measure the number of singlet metastable helium, He (21S), particles created from energetic protons. The group achieved the selective ionization of the excited state of an atom at nearly 100% efficiency by using pulsed laser light to pass a beam of protons into the helium gas cell. The experiment on singlet metastable helium atoms was seminal in the journey towards using resonance ionization spectroscopy (RIS) for extensive atomic analysis in research settings.

Melvin Miles was granted in 2004 a patent for a cold fusion device, and in 2007 he described his efforts to remove all instances of "cold fusion" from the patent description to avoid having it rejected outright. At least one patent related to cold fusion has been granted by the European Patent Office. A patent only legally prevents others from using or benefiting from one's invention. However, the general public perceives a patent as a stamp of approval, and a holder of three cold fusion patents said the patents were very valuable and had helped in getting investments.

=== 9/11 response === Following the September 11, 2001, terrorist attacks, President George W. Bush issued Executive Order 13224 under the IEEPA to block the assets of terrorist organizations. The president delegated blocking authority to federal agencies led by the U.S. Treasury. In October 2001, Congress passed the USA PATRIOT Act which, in part, enhanced IEEPA asset blocking provisions under §1702(a)(1)(B) to permit the blocking of assets during the "pendency of an investigation." This statutory change gave the Treasury's Office of Foreign Assets Control the power to block assets without the need to provide evidence of the blocking subject's wrongdoing nor to permit the blocking subject a chance to effectively respond to the allegations in court. Executing these blocking actions led to a series of legal cases challenging federal authority to indefinitely prevent charitable organizations from accessing their assets held in the United States.

== Structure == It is secreted as a single inactive polypeptide and is cleaved by serine proteases into a 69-kDa alpha-chain and 34-kDa beta-chain. A disulfide bond between the alpha and beta chains produces the active, heterodimeric molecule. The protein belongs to the plasminogen subfamily of S1 peptidases but has no detectable protease activity.

Large centralised markets have existed in Hong Kong since at least 16 May 1842, when Central Market was opened. These markets are most frequented by older residents, those with lower incomes, and domestic helpers who serve approximately 10 percent of Hong Kong's residents. Most neighbourhoods contain at least one such market. They have become destinations for tourists to "see the real Hong Kong". Prior to 2000, many of Hong Kong's public markets were managed by the Urban Council (within Hong Kong Island and Kowloon) or the Regional Council (in the New Territories). Since 2000, Hong Kong's public markets have been regulated by the Food and Environmental Hygiene Department. Under the Slaughterhouse Regulation, the slaughtering of live bovine animals, swine, goats, sheep or soliped for human consumption must take place in a licensed slaughterhouse, None of the markets in Hong Kong hold wild or exotic animals. In 2018, the FEHD operated 74 markets housing approximately 13,070 stalls. In addition, the Hong Kong Housing Authority operated 21 markets while private developers operated about 99 (in 2017).

Sources: en.wikipedia.org

Background from the literature

Researchers have developed a method to efficiently produce substantial quantities of heterologous viral glycoproteins within the allantoic cavity of embryonated chicken eggs. This technique utilizes a Sendai virus minigenome as a vector to express soluble variants of specific proteins, notably the human respiratory syncytial virus (HRSV) and human metapneumovirus (HMPV) fusion (F) proteins. These proteins are engineered without their transmembrane and cytoplasmic domains, facilitating their solubility. Overview of the methodology:

Psychopathology is the study of mental illness, particularly of severe disorders. Informed heavily by both psychology and neurology, its purpose is to classify mental illness, elucidate its underlying causes, and guide clinical psychiatric treatment accordingly. Although diagnosis and classification of mental norms and disorders is largely the purview of psychiatry—the results of which are guidelines such as the Diagnostic and Statistical Manual of Mental Disorders, which attempt to classify mental disease mostly on behavioural evidence, though not without controversy—the field is also heavily, and increasingly, informed upon by neuroscience and other of the biological cognitive sciences. Mental or social disorders or behaviours seen as generally unhealthy or excessive in a given individual, to the point where they cause harm or severe disruption to the person's lifestyle, are often called "pathological" (e.g., pathological gambling or pathological liar).

=== Sonic spray ionization === Sonic spray ionization is method for creating ions from a liquid solution, for example, a mixture of methanol and water. A pneumatic nebulizer is used to turn the solution into a supersonic spray of small droplets. Ions are formed when the solvent evaporates and the statistically unbalanced charge distribution on the droplets leads to a net charge and complete desolvation results in the formation of ions. Sonic spray ionization is used to analyze small organic molecules and drugs and can analyze large molecules when an electric field is applied to the capillary to help increase the charge density and generate multiple charged ions of proteins. Sonic spray ionization has been coupled with high performance liquid chromatography for the analysis of drugs. Oligonucleotides have been studied with this method. SSI has been used in a manner similar to desorption electrospray ionization for ambient ionization and has been coupled with thin-layer chromatography in this manner.

Some common side effects include burning and stinging sensations. Colour change of the skin, bump formation on the skin and additional hair growth could also occur. It is recommended that a doctor be consulted if these side effects persist or become worse. Some severe side effects are severe rash, swelling of the skin, and skin infection. Rare but serious allergic reactions, also known as anaphylaxis, can also occur. In the event that any of these side effects are encountered, patients are advised to approach a doctor immediately. Adverse effects after a long-term use of topical hydrocortisone include adrenal gland disorders. This problem can be more severe when excess topical hydrocortisone are used for a prolonged period of time. Other adverse effects include blurry vision, dizziness, fainting, unusual heartbeat, thirsty sensation, frequent urination, and fatigue. It is recommended that a doctor be informed if any of these symptoms occur. The impact of ingestion (eating) of such products has not been reported systematically, but a case report published in 2022 suggests this can lead to hospitalization and be potentially life threatening.

Sources: en.wikipedia.org

Frequently asked questions

What is AOD-9604?

AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.

Is AOD-9604 the same as growth hormone?

No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.

How is AOD-9604 regulated?

Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.

Has AOD-9604 been approved as a medicine?

No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.

Network